文献速递细菌感染、耐药与抗菌药物

头孢洛林治疗耐甲氧西林金黄色葡萄球菌血流感染:一项多中心回顾性队列研究

Ceftaroline for bloodstream infections caused by methicillin-resistant Staphylococcus aureus: a multicentre retrospective cohort study.
PubMed 文献 · Clin Microbiol Infect · 2024-11-23

这项在15家西班牙医院开展的多中心回顾性研究纳入429例成人MRSA血流感染,比较头孢洛林与万古霉素或达托霉素的疗效,发现30天死亡率无统计学显著差异,头孢洛林组不良事件发生率更高。

要点

  • 头孢洛林组30天死亡率为23.3%,标准治疗组为16.2%,差异无统计学意义(p=0.08)。
  • 倾向评分匹配后30天死亡率分别为21.9%和16.2%(p=0.38)。
  • 头孢洛林组不良事件发生率为12.0%,标准治疗组为4.4%(p<0.01)。

核心结论

  • 头孢洛林是MRSA血流感染的有效治疗选择,但常与联合用药同时使用,不良事件发生率较高。

研究设计与样本

  • 多中心回顾性队列研究,纳入西班牙15家医院2019年1月至2022年12月成人MRSA血流感染首次发作数据。
  • 头孢洛林组为血流感染起病第一周内使用头孢洛林≥72小时的患者,标准治疗组为起病后使用万古霉素或达托霉素≥72小时的患者。
  • 共纳入429例MRSA血流感染,头孢洛林组133例,标准治疗组296例。

主要发现

  • 头孢洛林组序贯器官衰竭评估评分>2者占51.1%,标准治疗组为36.5%(p<0.01)。
  • 头孢洛林组复杂性血流感染占66.2%,标准治疗组为42.2%(p<0.01)。
  • 头孢洛林组感染性心内膜炎占18.8%,标准治疗组为6.4%(p<0.01)。
  • 头孢洛林组联合治疗占65.4%,标准治疗组为11.5%(p<0.01)。
  • 30天全因死亡率头孢洛林组为23.3%(95% CI 16.1-30.5%),标准治疗组为16.2%(95% CI 12.0-20.4%),p=0.08。

关键数值与推荐

  • 90天死亡率头孢洛林组为33.1%,标准治疗组为26.7%(p=0.17)。
  • 倾向评分匹配后头孢洛林组105例与对照组105例,30天死亡率分别为21.9%和16.2%(p=0.38)。
  • 全队列Cox回归显示年龄与90天死亡风险相关(HR 1.05;95% CI 1.03-1.07),SOFA评分>2与90天死亡风险相关(HR 2.34;95% CI 1.50-3.65)。
  • 头孢洛林治疗对90天死亡风险无显著影响(HR 1.00;95% CI 0.97-1.02)。
  • 不良事件发生率头孢洛林组为12.0%,标准治疗组为4.4%(p<0.01)。

临床怎么用

  • 头孢洛林组不良事件多数发生于联合治疗时,联合治疗为17.2%,单药治疗为2.2%(p=0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effectiveness of ceftaroline vs. vancomycin or daptomycin in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections (BSIs) (MRSA-BSIs). METHODS: This multicentre retrospective study conducted in 15 Spanish hospitals included data from the first MRSA-BSIs of adult patients between January 2019 and December 2022. The ceftaroline group included patients who received ceftaroline for ≥72 hours within the first week of BSI onset; the standard-of-care (SOC) group included patients who received vancomycin or daptomycin ≥72 hours after BSI onset. Primary outcome was 30-day all-cause mortality; secondary outcomes included 90-day mortality and incidence of adverse events (AEs). Propensity-score matching and Cox proportional hazards analyses were performed. RESULTS: A total of 429 MRSA-BSIs were included: 133 in the ceftaroline group and 296 in the SOC group. More patients in the ceftaroline group had a Sequential Organ Failure Assessment score >2 (51.1% vs. 36.5%; p < 0.01), complicated BSI (66.2% vs. 42.2%; p < 0.01), infective endocarditis (18.8% vs. 6.4%; p < 0.01) and prescribed in combination treatment (65.4% vs. 11.5%; p < 0.01), with no statistically significant differences in 30-day mortality: 23.3% ceftaroline (95% CI, 16.1-30.5%) vs. 16.2% SOC (95% CI, 12.0-20.4%), p 0.08. There were no statistically significant differences in 90-day mortality (33.1% ceftaroline vs. 26.7% SOC; p 0.17). After propensity-score matching, 105 patients treated with ceftaroline were matched with 105 controls: the 30-day mortality rates were 21.9% and 16.2% (p 0.38). Cox regression analysis of the entire cohort (n = 429) revealed that age (hazard ratio [HR], 1.05; 95% CI, 1.03-1.07) and Sequential Organ Failure Assessment score >2 (HR, 2.34; 95% CI, 1.50-3.65) were associated with 90-day mortality risk, although ceftaroline treatment did not demonstrate a significant effect (HR, 1.00; 95% CI, 0.97-1.02). Incidence of AEs was 12.0% in ceftaroline vs. 4.4% in the SOC group (p < 0.01). Most AEs occurred when ceftaroline was used in combination vs. monotherapy (17.2% vs. 2.2%; p 0.01). DISCUSSION: Ceftaroline was an effective treatment for MRSA-BSIs but was commonly prescribed in combination showing a higher incidence of AEs.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Villa S, Escrihuela-Vidal F, Fernández-Hidalgo N, et al. Ceftaroline for bloodstream infections caused by methicillin-resistant Staphylococcus aureus: a multicentre retrospective cohort study. Clin Microbiol Infect. 2024. PMID: 39581546. doi:10.1016/j.cmi.2024.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。